Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian L Wiens

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Biopharmaceutical Statistics|October 22, 2013
Selection of hypothesis weights and ordering when testing multiple hypotheses in clinical trialsBrian L Wiens, Alex Dmitrienko, Olga Marchenko
Biometrical Journal. Biometrische Zeitschrift|October 22, 2008
General multistage gatekeeping proceduresAlex Dmitrienko, Ajit C Tamhane, Brian L Wiens
Therapeutic Innovation & Regulatory Science|September 21, 2018
Recent Statistical Contributions to Medical Device DevelopmentBrian L Wiens, Theodore C Lystig, Scott M Berry
Statistics in Medicine|October 21, 2006
Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectivesAlex Dmitrienko, Brian L Wiens, Ajit C Tamhane, et al.
Statistics in Medicine|May 20, 2008
A note on tree gatekeeping procedures in clinical trialsAlex Dmitrienko, Ajit C Tamhane, Lingyun Liu, et al.
The New England Journal of Medicine|May 28, 2016
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsAlexander T Cohen, Robert A Harrington, Samuel Z Goldhaber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyCharles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, et al.
Lancet (London, England)|September 15, 2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trialMichael A Weber, Henry Black, George Bakris, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 6, 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black, George L Bakris, Michael A Weber, et al.
The New England Journal of Medicine|November 13, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor ActivityDeborah M Siegal, John T Curnutte, Stuart J Connolly, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|October 22, 2013
Selection of hypothesis weights and ordering when testing multiple hypotheses in clinical trialsBrian L Wiens, Alex Dmitrienko, Olga Marchenko
Biometrical Journal. Biometrische Zeitschrift|October 22, 2008
General multistage gatekeeping proceduresAlex Dmitrienko, Ajit C Tamhane, Brian L Wiens
Therapeutic Innovation & Regulatory Science|September 21, 2018
Recent Statistical Contributions to Medical Device DevelopmentBrian L Wiens, Theodore C Lystig, Scott M Berry
Statistics in Medicine|October 21, 2006
Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectivesAlex Dmitrienko, Brian L Wiens, Ajit C Tamhane, et al.
Statistics in Medicine|May 20, 2008
A note on tree gatekeeping procedures in clinical trialsAlex Dmitrienko, Ajit C Tamhane, Lingyun Liu, et al.
The New England Journal of Medicine|May 28, 2016
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical PatientsAlexander T Cohen, Robert A Harrington, Samuel Z Goldhaber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III studyCharles L Vogel, Marek Z Wojtukiewicz, Robert R Carroll, et al.
Lancet (London, England)|September 15, 2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trialMichael A Weber, Henry Black, George Bakris, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|October 6, 2007
Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black, George L Bakris, Michael A Weber, et al.
The New England Journal of Medicine|November 13, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor ActivityDeborah M Siegal, John T Curnutte, Stuart J Connolly, et al.
Pageof 3